The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Open accessAbstract
BACKGROUND: Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein (LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse events; its effects on cardiovascular outcomes remain uncertain. METHODS: We conducted a double-blind, randomized, placebo-controlled trial involving patients who were unable or unwilling to take statins owing to unacceptable adverse effects ("statin-intolerant" patients) and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. RESULTS: A total of 13,970 patients underwent randomization; 6992 were assigned to the bempedoic acid group and 6978 to the placebo group. The median duration of follow-up was 40.6 months. The mean LDL cholesterol level at baseline was 139.0 mg per deciliter in both groups, and after 6 months, the reduction in the level was greater with bempedoic acid than with placebo by 29.2 mg per deciliter; the observed difference in the percent reductions was 21.1 percentage points in favor of bempedoic acid. The incidence of a primary end-point event was significantly lower with bempedoic acid than with placebo (819 patients [11.7%] vs. 927 [13.3%]; hazard ratio, 0.87; 95% confidence interval [CI], 0.79 to 0.96; P = 0.004), as were the incidences of a composite of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (575 [8.2%] vs. 663 [9.5%]; hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P = 0.006); fatal or nonfatal myocardial infarction (261 [3.7%] vs. 334 [4.8%]; hazard ratio, 0.77; 95% CI, 0.66 to 0.91; P = 0.002); and coronary revascularization (435 [6.2%] vs. 529 [7.6%]; hazard ratio, 0.81; 95% CI, 0.72 to 0.92; P = 0.001). Bempedoic acid had no significant effects on fatal or nonfatal stroke, death from cardiovascular causes, and death from any cause. The incidences of gout and cholelithiasis were higher with bempedoic acid than with placebo (3.1% vs. 2.1% and 2.2% vs. 1.2%, respectively), as were the incidences of small increases in serum creatinine, uric acid, and hepatic-enzyme levels. CONCLUSIONS: Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). (Funded by Esperion Therapeutics; CLEAR Outcomes ClinicalTrials.gov number, NCT02993406.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The CLEAR Outcomes trial randomized 13,970 patients with established or high risk for CVD, intolerance to statins, and LDL-C level ≥ 100 mg/dL to receive bempedoic acid (180 mg daily) or placebo [131]. Bempedoic acid reduced the risk of MACE by − 13% (HR 0.87, 95% CI 0.79–0.96, p = 0.004) and resulted in a − 21.1% greater reduction in LDL-C levels”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [133]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is important to note that ∼19% of individuals were on very-low-dose statin therapy at baseline (135).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [135]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This substantially exceeded other oral non-statin therapies, as ezetimibe lowers LDL-C by 18–25%, bempedoic acid by 17–21%, and their combination by ∼36–40% [[21], [22], [23], [24]]”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the CLEAR-Outcomes trial, an intriguing observation was that BA’s relative risk reduction for the primary composite outcome differed significantly between the primary and secondary prevention groups (with hazard ratios of 0.68 versus 0.91 respectively) [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A higher frequency of gout (3.1% versus 2.1%) and cholelithiasis (2.2% versus 1.2%) was observed with bempedoic acid than with placebo [133].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [133]
The cited source says what the claim attributes to it.
In the citing paper
“The Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid or Placebo (CLEAR Outcomes) trial found a reduction in four-point major adverse cardiovascular events by 13% compared with placebo for individuals with established ASCVD (70% of population) or at high risk for ASCVD (30% of population) a”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical trials have shown bempedoic acid reduces LDL-C levels and the CLEAR Outcomes trial demonstrated a significant reduction in MACE compared with placebo in patients who are statin intolerant [[12], [13], [14], [15],17].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The CLEAR Outcomes (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) trial reported cardiovascular outcomes in a mixed population of primary and secondary prevention patients unable or unwilling to take guideline-recommended doses of statins.11”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“This primary prevention cohort was a prespecified subgroup that represented 30% of the total enrolled within a larger trial that included a mixed population of primary and secondary prevention patients.11”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“This was followed by recent data from the CLEAR Outcomes trial showing reductions in clinical events [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“These differences are likely attributable to a lack of statistical power and imprecise estimates as the largest outcomes-based trial, CLEAR Outcomes, had not yet been published at the time of the previous meta-analyses but is included in our meta-analysis [7].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, most of the trials included in this analysis had relatively short follow-up durations with the exception of CLEAR Outcomes [7] and CLEAR Harmony [12].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The overall risk of bias was low 7 of 11 trials [7, 9–12, 15, 16], with 4 trials being assessed as having a moderate risk of bias [8, 13, 14, 17].”
From The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Among the 6992 patients assigned to the active arm of the study 45% had T2DM.Bempedoic acid was associated with a significantly lower incidence of the four-component composite primary endpoint of CV death, non-fatal MI, non-fatal stroke, or coronary revascularization and a higher incidence of some adverse events (gout and cholelithiasis) at the 40.6 month follow-up.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [282]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationStatins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Self-citationStroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationSafety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807
Self-citationPinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498
Goldberg, A. C., Leiter, L. A., Stroes, E. S. G., Baum, S. J., Hanselman, J. C., Bloedon, L. T., Lalwani, N. D., Patel, P. M., Zhao, X., & Duell, P. B. (2019) · JAMA · doi:10.1001/jama.2019.16585 · Cited by 481
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,000
Diretriz de Síndrome Coronariana Crônica – 2025
César, L. A. M., Gowdak, L. H. W., Pavanello, R., Ferreira, J. F. M., Mioto, B. M., Poppi, N. T., Mendonça, C. J. L., Beck, A. L. D. S., de Brito, A. S. X., Abizaid, A., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250619 · Cited by 14
Integrating genetic data with biological insight: A practical guide to cis-Mendelian randomization
Karhunen, V., Woolf, B. A. R., Bhatnagar, P., Gill, D., & Burgess, S. (2026) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2026.03.011 · Cited by 13
Sun, Q., Guo, Y., Hu, W., Zhang, M., Wang, S., Lei, Y., Meng, H., Li, N., Xu, P., Li, Z., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001449 · Cited by 13
Self-citationBempedoic acid: new evidence and recommendations on use
Paponja, K., Pećin, I., Reiner, Ž., & Banach, M. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000911 · Cited by 13
Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance
Li, J., Dou, K., Zhou, Z., Zhao, D. H., Ye, P., Chen, H., Chen, Z., Peng, D., Guo, Y., Wu, N., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3213 · Cited by 13
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?
Jamil, Y., Cohen, R., Alameddine, D., Deo, S. V., Kumar, M., & Orkaby, A. R. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01224-4 · Cited by 13
Vladimirov, S. S., Tomasevic, M., Popov, N., Munjas, J., de Gonzalo‐Calvo, D., & Sopić, M. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.005 · Cited by 14
Inflammation reprogramming and immunomodulation: Next-generation treatments for atherosclerosis
Choudhury, R. P., Hargreaves, R., Chai, J., & Fisher, E. A. A. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102288 · Cited by 12
Katamine, M., Minami, Y., & Ako, J. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22044 · Cited by 12
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 14
Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 12
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 13
Katzmann, J. L., Stürzebecher, P. E., Kruppert, S., & Laufs, U. (2024) · Scientific Reports · doi:10.1038/s41598-023-50847-1 · Cited by 12
PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention
Marco-Benedí, V., Sánchez-Hernández, R. M., Díaz-Díaz, J. L., Jarauta, E., Tembra, M. S., Pintó, X., Morillas, C., Plana, N., Pedro‐Botet, J., & Civeira, F. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02283-x · Cited by 12
Effectiveness of screening for foot complications in people with diabetes – A systematic review
Staniszewska, A., Jones, A., Rudd, S., de Vocht, F., & Hinchliffe, R. J. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108865 · Cited by 12
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12
Puertas-Umbert, L., Alonso, J., Blanco-Casoliva, L., Almendra‐Pegueros, R., Camacho, M., Rodríguez‐Sinovas, A., Galán, M., Roglans, N., Laguna, J. C., Martínez‐González, J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117876 · Cited by 12
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12
Self-citationMancini, G. B. J., Ryomoto, A., Yeoh, E., Iatan, I., Brunham, L. R., & Hegele, R. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf048 · Cited by 12
Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering
Malick, W. A., Choi, D., Langsted, A., Bittner, V., Nordestgaard, B. G., Stroes, E. S. G., & Rosenson, R. S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf123 · Cited by 14
Yamashita, S., Kiyosue, A., Fujita, H., Yokota, D., Nakamura, Y., & Yasuda, S. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0089 · Cited by 12
A Critical Appraisal of Lipid Management in the Post-Statin Era
Spitz, J. A., Patel, J., Agarwala, A., Sharma, G. V., Mehta, A., Natarajan, P., Nasir, K., Morris, P. B., Blumenthal, R. S., & Shapiro, M. D. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101823 · Cited by 12
McCarthy, C. P., Ballantyne, C. M., Blankstein, R., Budoff, M. J., Ditmarsch, M., Gibson, C. M., Kastelein, J. J. P., Návar, A. M., Nicholls, S. J., Ray, K. K., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.07.012 · Cited by 12
Self-citationLiang, K., Wang, Q., Qiu, L., Gong, X., Chen, Z., Zhang, H., Ding, K., Liu, Y., Wei, J., Lin, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115658 · Cited by 12
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Singh, A., & Cho, L. S. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23058 · Cited by 12
Self-citationBenefits of Bempedoic Acid — Clearer Now
Alexander, J. H. (2023) · New England Journal of Medicine · doi:10.1056/nejme2301490 · Cited by 12
Cordero, A., Santos‐Gallego, C. G., Manzanas, A. O., Rodríguez‐Mañero, M., Fernández-Olmo, R., & Quesada, A. J. (2025) · European Cardiology Review · doi:10.15420/ecr.2025.16 · Cited by 11
Xu, Q., Cheng, A., Li, B., Tian, X., Han, Z., & Feng, Z. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12427 · Cited by 11
Overcoming patient reluctance to statin intolerance
Katamesh, B. E., Mickow, A., Huang, L., Dougan, B. M., Ratrout, B. M., Nanda, S., & Vincent, A. (2024) · Kardiologia Polska · doi:10.33963/v.phj.100526 · Cited by 11
Leiter, L. A., Hegele, R. A., Brown, V., Bergeron, J., Mackinnon, E. S., & Mancini, G. B. J. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2505190 · Cited by 12
Biju, A. K., Lakshmikumar, R. R. C., & Rengasamy, K. R. R. (2024) · Natural Resources for Human Health · doi:10.53365/nrfhh/189500 · Cited by 11
Statin-Associated Muscle Symptoms: Identification and Recommendations for Management
Maki, K. C., Kirkpatrick, C. F., Cheeley, M. K., & Jacobson, T. A. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01246-y · Cited by 11
Lolekha, P., Khovidhunkit, W., Deerochanawong, C., Thongtang, N., Boonyasirinant, T., Rattarasarn, C., Chutinet, A., Ophascharoensuk, V., Somlaw, N., Sitthisook, S., et al. (2024) · Asian Biomedicine · doi:10.2478/abm-2024-0033 · Cited by 13
Debate: Lipid-lowering Therapies and Diabetes Development
Brandts, J., & Müller‐Wieland, D. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01270-y · Cited by 12
Approach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 12
Fuerlinger, A., Stockner, A., Sedej, S., & Abdellatif, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02566-8 · Cited by 12
Morton, J. I., Liew, D., Watts, G. F., Zoungas, S., Nicholls, S. J., Dixon, P., & Ademi, Z. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf114 · Cited by 11
Self-citationGreenberg, G. S., Lorenzatti, D., Filtz, A., Jaspan, V. N., Park, C. M., Kalich, B. A., Kathe, N. J., Sidelnikov, E., Palo, K. E. D., Browne, C., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf235 · Cited by 11
Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly
Baratta, F., Moscucci, F., Lospinuso, I., Cocomello, N., Colantoni, A., Costanzo, A. D., Tramontano, D., D’Erasmo, L., Pastori, D., Ettorre, E., et al. (2025) · Drugs · doi:10.1007/s40265-025-02182-0 · Cited by 11
HDL Function Versus Small Dense LDL: Cardiovascular Benefits and Implications
Stoicescu, C. I., Văcărescu, C., & Cozma, D. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144945 · Cited by 11
Obicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence
Bhatti, M. I., Safiullah, M., Farhan, K., Ali, A., Abdullah, S., Ali, A., & Ahmed, R. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.003 · Cited by 11
Shapiro, M. D., Taub, P. R., Louie, M. J., Lei, L., & Ballantyne, C. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.973 · Cited by 12
Self-citationCowart, K., Singleton, J., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.06.011 · Cited by 11
Goldberg, A. C., Banach, M., Catapano, A. L., Duell, P. B., Leiter, L. A., Hanselman, J. C., Lei, L., & Mancini, G. B. J. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117192 · Cited by 11
Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials
Cordero, A., Olmo, R. F., Santos‐Gallego, C. G., Fácila, L., Bonanad, C., Castellano, J. M., Rodríguez‐Mañero, M., Seijas‐Amigo, J., González‐Juanatey, J. R., & Badimón, J. J. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.07.145 · Cited by 11
Mechanism of bempedoic acid induced cholelithiasis: A role for statins to limit this adverse effect?
Ferri, N., & Corsini, A. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106900 · Cited by 11
Giordano, S. A., Franchi, F., Rollini, F., Saleh, T. A., Uzunoglu, E. C., Costa, F., Angiolillo, D. J., & Ortega‐Paz, L. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.23.06411-6 · Cited by 11
HIV-associated dyslipidemia: pathogenesis and its management
Wan, Z., Dai, B., Zhu, X., Huang, Y., & Zhu, B. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002879 · Cited by 11
Preventive Therapies in Peripheral Arterial Disease
Shah, A. J., Pavlatos, N., & Kalra, D. K. (2023) · Biomedicines · doi:10.3390/biomedicines11123157 · Cited by 12
Raposeiras‐Roubín, S., Assi, E. A., Jiménez-Méndez, C., de la Guía, E. M., Pérez-Rivera, J.-Á., Mangas, M. M., Ayesta, A., Uribarri, A., Jorge‐Pérez, P., Muiños, P. J. A., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.075388 · Cited by 10
Geschlechterspezifische Aspekte kardiovaskulärer Erkrankungen
Baessler, A., Bauer, P., Becker, M., Berrisch-Rahmel, S., Goldmann, B. U., Grünig, E., Hamm, C., Meder, B., Kindermann, I., Ong, P., et al. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00694-9 · Cited by 11
Vivas, D., Escobar, C., Cordero, A., Fernández-Olmo, R., Oterino, A., Blanco-Echevarría, A., Botana, M., Escribano, D., Freijo, M. D. M., Losas, P. M., et al. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.06.002 · Cited by 10
El colesterol LDL como agente causal de la aterosclerosis
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.07.001 · Cited by 10
Metabolic Syndrome and Pharmacological Interventions in Clinical Development
Javor, E., Šarčević, D., & Rešić, A. (2024) · Diabetology · doi:10.3390/diabetology5030023 · Cited by 9
Laufs, U., Lincoff, A. M., Nicholls, S. J., Li, N., Bloedon, L. T., Sasiela, W. J., Powell, H. A., Herout, P. M., Thompson, P. D., & Nissen, S. E. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.014 · Cited by 10
Self-citationManagement of dyslipidaemia in patients with comorbidities—facing the challenge
Frühwald, L., Fasching, P., Dobrev, D., Kaski, J. C., Borghi, C., Waßmann, S., Huber, K., Semb, A. G., Agewall, S., & Drexel, H. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae095 · Cited by 10
Prescriber Uptake and Use of Novel Lipid‐Lowering Therapies
Hwang, J., Peterson, E. D., Gupta, A., Decicco, E., Sarnes, E., & Návar, A. M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.040768 · Cited by 10
Владиславович, Е. М., Kukharchuk, V. V., Балахонова, Т. В., Gurevich, V. S., Сергиенко, И. В., Sokolov, A. A., Анатольевич, С. А., Иосифович, Ш. И., Ахмеджанов, Н. М., Барбараш, О. Л., et al. (2025) · Eurasian heart journal · doi:10.38109/2225-1685-2025-2-6-34 · Cited by 10
Reshaping Dyslipidaemia Treatment with Bempedoic Acid—A Narrative Review
Strikić, D., Begic, Z., Radman, I. B., Zlopasa, F., Mateljic, J., Zec, I., Titlić, M., Slišković, A. M., Pećin, I., Reiner, Ž., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061460 · Cited by 10
Chronic Coronary Artery Disease
Kittleson, M. M. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03512 · Cited by 10
Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction
Alhomoud, I. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1727918 · Cited by 10
A practical guide to the management of dyslipidaemia
Siegel, P. M., Katzmann, J. L., Weinmann‐Menke, J., Landmesser, U., Schunkert, H., Baldus, S. E., Böhm, M., Laufs, U., Lüscher, T. F., & Hilgendorf, I. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02833-y · Cited by 10
Bempedoic acid directly binds and activates PPARα
Papa, C., Rose, A., Martin, H., Useini, A., Florian, G., Liao, L., Rodríguez‐Aguilera, J. R., Allo, P. V., Hoffmann, A., Tvardovskiy, A., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.12.018 · Cited by 10
Verghese, D., Muller, L., & Velamakanni, S. V. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01923-5 · Cited by 10
Clegg, K., Schubert, T. J., Block, R., Burke, F., Desai, N. R., Greenfield, R. S., Karalis, D. G., Kris‐Etherton, P. M., McNeal, C. J., Nahrwold, R., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.07.007 · Cited by 10
Venkatraman, S., Das, S., Eerike, M., Cherian, J. J., & Bagepally, B. S. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03555-8 · Cited by 10
Jacobsen, A. P., Whelton, S. P., Blumenthal, R. S., & McEvoy, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00042-6 · Cited by 13
Sex differences in the perception of cardiovascular risk in familial hypercholesterolemia
Alshibani, B., Iatan, I., Guérin, A., Ruel, I. L., Cermakova, L., Ramanakumar, A. V., Pilote, L., Coutinho, T. A., Brunham, L. R., & Genest, J. J. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.10.007 · Cited by 10
Wright, J., & Subramanian, S. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.005 · Cited by 10
Iannuzzo, G., Kamboj, G., Barman, P., Dongare, S., & Jawla, S. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.10.001 · Cited by 10
Bempedoic Acid and the Prevention of Cardiovascular Disease
Keaney, J. F. (2023) · New England Journal of Medicine · doi:10.1056/nejme2300793 · Cited by 10
Effects of bempedoic acid on markers of inflammation and Lp(a)
Reddy, S., & Deoker, A. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001137 · Cited by 9
Inequities in atherosclerotic cardiovascular disease prevention
Gomez, S. E., Dudum, R., & Rodríguez, F. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.05.002 · Cited by 9
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials
Savage, P., Cox, B., Shahmohammadi, M., Kelly, B. P., & Menown, I. B. A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02877-y · Cited by 9
Targeting metabolic pathway enhance CAR-T potency for solid tumor
Li, W., Chen, J., & Guo, Z. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113412 · Cited by 9
Acetyl-CoA synthesis in the skin is a key determinant of systemic lipid homeostasis
Nguyen, P. T., Shiue, M., Kuprasertkul, N., Costa‐Pinheiro, P., Izzo, L., Pinheiro, L. V., Affronti, H. C., Gugiu, G. B., Ghaisas, S., Liu, J. Y., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115284 · Cited by 12
Impact of Sex Differences on Lipids and Statin Utilization
Rodriguez, C. P., Burka, S., & Michos, E. D. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01286-y · Cited by 9
Integrating New Technologies in Lipidology: A Comprehensive Review
Escobar, C., García, J. S., Torremocha, A., Lorenzo, C. C., Lara-García, A., Muñoz, L. C., González, R. M., García, J. V., & Banach, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144984 · Cited by 10
Karalis, D. G. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000896 · Cited by 9
Atherosclerotic Cardiovascular Disease in Women: Providing Protection With Lipid-altering Agents
Hiles, M., Simmons, A., Hilleman, D. E., Gibson, C., & Backes, J. M. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.08.021 · Cited by 9
Ogungbe, O., Grant, J. K., Ayoola, A., Bansah, E. C., Miller, H., Plante, T. B., Sheikhattari, P., Commodore-Mensah, Y. Y., Turkson‐Ocran, R., Juraschek, S. P., et al. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01942-2 · Cited by 9
Lin, Y., Zhou, F., Wang, X., Guo, Y., & Chen, W. (2023) · PeerJ · doi:10.7717/peerj.15969 · Cited by 9
Tokgözoğlu, L. S., Pirillo, A., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad485 · Cited by 9
Apple, S. J., Clark, R. E., Daich, J., González, M. L., Ostfeld, R. J., Toth, P. P., Bittner, V., Martin, S. S., Rana, J. S., Nasir, K., et al. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412350 · Cited by 10
Dyslipidemia and peripheral arterial disease
Yadav, A. K., Sawant, V., Bedi, V. S., & Yadav, K. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.010 · Cited by 9
Kayani, T., Ahmad, B., Chang, R., Qian, F., Sahinoz, M., Rehan, M., Giaimo, A., Spatz, E. S., & Hu, J. (2024) · Pharmacoepidemiology · doi:10.3390/pharma3010009 · Cited by 9
Reddin, C., Stankard, A., Chan, K. Y., Krewer, F., Judge, C., Canavan, M., Davis, D. H. J., & O’Donnell, M. (2025) · Age and Ageing · doi:10.1093/ageing/afaf219 · Cited by 8
Bays, H. E., Bloedon, L. T., Brennan, D. M., Lei, L., Lincoff, A. M., Nicholls, S. J., Plutzky, J., Powell, H. A., & Nissen, S. E. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037898 · Cited by 8
Self-citationRusso, V., Ratti, G., Parrella, A., De Falco, A., Crisci, M., Franco, R., Covetti, G., Caturano, A., Napolitano, G., Scotto di Uccio, F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061839 · Cited by 8
Sedrakyan, S., Nadeem, B., Gaughran, D., Sinauridze, A., Georgy, A., Hurley, S., & Lam, U. T. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.05.029 · Cited by 8
Lipid-lowering agents in solid organ transplant recipients
Mickiewicz, A., Żegleń, S., Kędzierska-Kapuza, K., Heleniak, Z., Frankiewicz, A., Adamczyk, E., Wełnicki, M. T., Wawrzynowicz‐Syczewska, M., Raszeja‐Wyszomirska, J., Durlik, M., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf104 · Cited by 8
Zhou, X., Gu, Y., & Li, L. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123620 · Cited by 8
Saito, Y., Tateishi, K., Kato, K., Kitahara, H., & Kobayashi, Y. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5950-25 · Cited by 8
Li, D., Liu, Z., & Jiang, H. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02862-0 · Cited by 8
Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities
Evans, P. C., Vilahur, G., Kleinbongard, P., Osto, E., Remme, C. A., Madonna, R., Aksentijević, D., Sourij, H., Davidson, S. M., Santovito, D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag116 · Cited by 8
Uddin, N., Syed, A. A., Ismail, S. M., Ashraf, M. T., Khan, M. K., & Sohail, A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102003 · Cited by 8
Schiele, F., Catapano, A. L., Caterina, R. D., Laufs, U., Jukema, J. W., Zaman, A., & Sionís, A. (2023) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad119 · Cited by 8
Li, Y., Gao, H., Zhao, J., Ma, L., & Hu, D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297854 · Cited by 8
Afzal, M. A., Khalid, N., Abdullah, M., Haiy, A. U., Hassan, M. A., Sana, H., Elkattawy, S., Malik, A. A., Michael, P., Vasudev, R., et al. (2024) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.55729/2000-9666.1305 · Cited by 8
Decoding the Intricacies of Statin-Associated Muscle Symptoms
Rastegar, T. F., Khan, I. A., & Christopher‐Stine, L. (2024) · Current Rheumatology Reports · doi:10.1007/s11926-024-01143-y · Cited by 8
Metadata
- Authors
- Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., Bays, H. E., Moriarty, P. M., Menon, V., Grobbee, D. E., Louie, M. J., Chen, C.-F., Li, N., Bloedon, L., Robinson, P., Horner, M., Sasiela, W. J., McCluskey, J., Davey, D., Fajardo-Campos, P., Petrovic, P., Fedacko, J., Zmuda, W., Lukyanov, Y., & Nicholls, S. J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cleveland Clinic, Cleveland (S.E.N., A.M.L., D.B., D.M., L.C., V.M., J.M., D.D.); Imperial College London, London (K.K.R.); University of Amsterdam Academic Medical Center, Amsterdam (J.J.P.K.), and University Medical Center Utrecht, Utrecht (D.E.G.) — both in the Netherlands; Hartford Hospital, Hartford, CT (P.D.T.); Brigham and Women’s Hospital, Harvard Medical School, Boston (P.L., J.P.); Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY (H.E.B.); University of Kansas Medical Center, Kansas City (P.M.M.); Esperion Therapeutics, Ann Arbor, MI (M.J.L., C.-F.C., N.L., L.B., P.R., M.H., W.J.S.); Centro de Investigación Cardiovascular y Metabólica, Tijuana, Mexico (P.F.-C.); General Hospital Sveti Luka, Smederevo, Serbia (P.P.); Center of Clinical and Preclinical Research Medipark, Pavol Jozef Šafárik University, Košice, Slovakia (J.F.); Medicome, Oświęcim, Poland (W.Z.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (Y.L.); and Victorian Heart I...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-04-13
- Volume
- 388
- Issue
- 15
- Pages
- 1353-1364
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4323075797
- Semantic Scholar
- 33b876475ba15ddd5ffc66ad5046afe4cb9173b0
- Cited by
- 988
- References
- 21
- Citations by year
- 2026: 266 · 2025: 261 · 2024: 270 · 2023: 189
- FWCI
- 263.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Esperion Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, statin intolerance, ATP-citrate lyase inhibitor, LDL cholesterol lowering, major adverse cardiovascular events, cardiovascular disease prevention, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, hypercholesterolemia, lipid-lowering therapy, statin adverse effects
- MeSH terms
- Administration, Oral, Hypolipidemic Agents, Cardiovascular Diseases, Dicarboxylic Acids, Double-Blind Method, Fatty Acids, Humans, Myocardial Infarction, Myocardial Revascularization, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
